IL-18 binding protein fusion construct delays the development of diabetes in adoptive transfer and cyclophosphamide-induced diabetes in NOD mouse

Clinical Immunology

Volumn 115, Issue 1 SPEC. ISS., 2005, Pages 74-79

  Zaccone, Paola ^a   Phillips, Jenny ^a   Conget, Ignacio ^b,c   Cooke, Anne ^a   Nicoletti, Ferdinando ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Interleukin 18; NOD mouse; Type 1 diabetes mellitus

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNITY; CELL FUNCTION; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; EVALUATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

EID: 18144390563     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.11.007     Document Type: Conference Paper

References (27)

1. A. Rabinovitch An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus Diabetes Metab. Rev. 14 1998 129 151
2. D.L. Eizirik, and T. Mandrup-Poulsen Choice of death- the signal-transduction of immune-mediated β-cell apoptosis Diabetologia 44 2001 2115 2133
3. C.A. Dinarello IL-18: a TH1-inducing proinflammatory cytokine and new member of the IL-1 family J. Allergy Clin. Immunol. 103 1999 11 24
4. P.V. Sivakumar, G.M. Westrich, S. Kanaly, K. Garka, T.L. Born, J.M. Derry, and J.L. Viney Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage Gut 50 2002 812 820
5. C. Plater-Zyberk, L.A. Joosten, M.M. Helsen, P. Sattonnet-Roche, C. Siegfried, S. Alouani, F.A. van De Loo, P. Graber, S. Aloni, R. Cirillo, E. Lubberts, C.A. Dinarello, W.B. van Den Berg, and Y. Chvatchko Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis J. Clin. Invest. 108 2001 1825 1832
6. R. Faggioni, R.C. Cattley, J. Guo, S. Flores, H. Brown, M. Qi, S. Yin, D. Hill, S. Scully, C. Chen, D. Brankow, J. Lewis, C. Baikalov, H. Yamane, T. Meng, F. Martin, S. Hu, T. Boone, and G. Senaldi IL-18 binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice J. Immunol. 167 2001 5913 5920
7. S. Yu, Z. Chen, E. Mix, S.-W. Zhu, B. Winblad, H.-G. Ljunggren, and J. Zhu Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter regulation of autoreactive Th1 responses to peripheral myelin antigen J. Neuropathol. Exp. Neurol. 61 2002 614 622
8. J.A. Gracie, R.J. Forsey, W.L. Chan, A. Gilmour, B.P. Leung, M.R. Greer, K. Kennedy, R. Carter, X.-Q. Wei, D. Xu, M. Field, A. Foulis, F.Y. Liew, and I.B. McInnes A proinflammatory role for IL-18 in rheumatoid arthritis J. Clin. Invest. 104 1999 1393 1401
9. E. Esfandiari, I.B. McInnes, G. Lindop, F.-P. Huang, M. Field, M. Komai-Koma, X.-Q. Wei, and F.Y. Liew A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease J. Immunol. 167 2001 5338 5347
10. F. Nicoletti, I. Conget, R. Di Marco, A.M. Speciale, R. Morìnigo, K. Bendtzen, and R. Gomis Serum levels of the interferon-g-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type 1 diabetes Diabetologia 44 2001 309 311
11. A. Kretwoski, K. Mironczuk, A. Karpinska, U. Boojaryn, M. Kinalski, Z. Pulchalski, and I. Kinalska Interleukin-18 promoter polymorphisms in type 1 diabetes Diabetes 51 2002 3347 33479
12. A. Ide, E. Kawasaki, N. Abiru, F. Sun, M. Kobayashi, T. Fukushima, R. Takahashi, H. Kuwahara, A. Kita, K. Oshima, S. Uotani, I. Yamasaki, Y. Yamaguchi, and K. Euguki Association between IL-18 gene promoter polymorphism and CTLA-4 gene 49 A/G polymorphysm in Japanese patients with type 1 diabetes J. Autoimmun. 22 2004 73 78
13. R.L. Nolsoe, F. Pociot, D. Novick, M. Rubinstein, S.H. Kim, C.A. Dinarello, T. Mandrup-Poulsen, and N.Y. Ann Mutation scan of a type 1 diabetes candidate gene: the human interleukin-18 binding protein gene Acad. Sci. 1005 2003 332 339
14. F. Nicoletti, R. Di Marco, G. Papaccio, I. Conget, R. Gomis, R. Bernardini, J.E. Sims, Y. Shoenfeld, and K. Bendtzen Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycaemia and insulitis by a recombinant IL-18-binding protein: Fc construct Eur. J. Immunol. 33 2003 2278 2286
15. M.L. Lukic, E. Mensah-Brown, X. Wei, A. Shanin, and F. Liew Lack of mediators of innate immunity attenuate the development of autoimmune diabetes in mice J. Autoimmun. 21 2003 239 246
16. S. Frigerio, G.A. Hollander, and U. Zumsteg Functional IL-18 is produced by primary pancreatic mouse islet and NIT-1β cells and participates in the progression towards destructive insulitis Horm. Res. 57 2002 94 104
17. J. Rothe, N.A. Jenkins, N.G. Copeland, and H. Kolb Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2 J. Clin. Invest. 99 1997 469 474
18. H. Rothe, A. Hausmann, K. Casteels, H. Okamura, M. Kurimoto, V. Bukart, C. Mathieu, and H. Kolb IL-18 inhibits diabetes development in non obese diabetic mice by counterregulation of Th1-dependent destructive insulitis J. Immunol. 163 1999 1230 1236
19. Y. Oikawa, A. Shimada, A. Kasuga, J. Morimoto, H. Tahara, T. Miyzaki, F. Tashiro, E. Yamato, J. Miyazaki, and T. Saruta Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice J. Immunol. 171 2003 5865 5875
20. T.L. Born, L.A. Morrison, D.J. Esteban, T. VandenBos, L.G. Thebeau, N. Chen, M.K. Spriggs, J.E. Sims, and R.M. Buller A poxvirus protein that binds to and inactivates IL 18 and inhibits NK cell response J. Immunol. 164 2000 3246 3254
21. F. Nicoletti, P. Zaccone, R. Di Marco, M. Lunetta, G. Magro, S. Grasso, P. Meroni, and G. Garotta Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-g antibody Endocrinology 138 1997 281 288
22. M. Drage, P. Zaccone, J.M. Phillips, F. Nicoletti, J. Dawson, J. Andrew Bradley, and A. Cooke Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice Transplantation 74 2002 611 619
23. F. Nicoletti, R. Di Marco, W. Barcellini, G. Magro, H.U. Schorlemmer, R. Kurrle, M. Lunetta, S. Grasso, P. Zaccone, and P. Meroni Protection from experimental autoimmune diabetes in the non obese diabetic mouse with soluble interleukin-1 receptor Eur. J. Immunol. 24 1994 1843 1847
24. I. Andre-Schmutz, C. Hindelang, C. Benoist, and D. Mathis Cellular and molecular changes accompanying the progression from insulitis to diabetes Eur. J. Immunol. 29 1999 245 255
25. H. Rothe, Y. Ito, and H. Kolb Disease resistant, NOD-related strains reveal checkpoints of immunoregulation in the pancreas J. Mol. Med. 79 2001 187 190
26. K. Nakanishi, T. Yoshimoto, H. Tsutsui, and H. Okamura Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu Cytokine Growth Factor Rev. 12 2001 53 72
27. K. Fujihira, M. Nagata, H. Moriyama, H. Yasuda, K. Arisawa, M. Nakayama, S. Maeda, M. Kasuga, K. Okumura, H. Yagita, and K. Yokono Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in the NOD mice Diabetes 49 2000 1998 2006